Literature DB >> 34416120

Contemporary Management of Thyroid Nodules.

Kristen Kobaly1, Caroline S Kim1, Susan J Mandel1.   

Abstract

Thyroid nodules are common in the general population, with higher prevalence in women and with advancing age. Approximately 5% of thyroid nodules are malignant; the majority of this subset represents papillary thyroid cancer. Ultrasonography is the standard technique to assess the underlying thyroid parenchyma, characterize the features of thyroid nodules, and evaluate for abnormal cervical lymphadenopathy. Various risk stratification systems exist to categorize the risk of malignancy based on the ultrasound appearance of a thyroid nodule. Nodules are selected for fine-needle aspiration biopsy on the basis of ultrasound features, size, and high-risk clinical history. Cytology results are classified by the Bethesda system into six categories ranging from benign to malignant. When cytology is indeterminate, molecular testing can further risk-stratify patients for observation or surgery. Surveillance is indicated for nodules with benign cytology, indeterminate cytology with reassuring molecular testing, or non-biopsied nodules without a benign sonographic appearance.

Entities:  

Keywords:  cytology; molecular testing; thyroid cancer; thyroid nodule; ultrasound

Mesh:

Year:  2021        PMID: 34416120     DOI: 10.1146/annurev-med-042220-015032

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  2 in total

1.  Risk factors and diagnostic prediction models for papillary thyroid carcinoma.

Authors:  Xiaowen Zhang; Yuyang Ze; Jianfeng Sang; Xianbiao Shi; Yan Bi; Shanmei Shen; Xinlin Zhang; Dalong Zhu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-05       Impact factor: 6.055

2.  Diagnostic performance of C-TIRADS in malignancy risk stratification of thyroid nodules: A systematic review and meta-analysis.

Authors:  Yan Hu; Shangyan Xu; Weiwei Zhan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-08       Impact factor: 6.055

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.